Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Vaxcyte, Inc. Vaxcyte Appoints John Furey to Board of Directors July 02, 2024 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update May 08, 2024 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference April 02, 2024 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants March 04, 2024 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update February 27, 2024 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 February 15, 2024 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares February 02, 2024 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference February 01, 2024 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte Announces Pricing of $750 Million Public Offering January 30, 2024 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants January 30, 2024 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older January 29, 2024 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte Appoints Whitney Jones as Chief People Officer January 16, 2024 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise January 04, 2024 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate December 04, 2023 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte Appoints Jacks Lee to Board of Directors November 28, 2023 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates November 27, 2023 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX STRO Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults November 09, 2023 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update November 06, 2023 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte to Present at Upcoming Investor Conferences October 31, 2023 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs) October 16, 2023 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference September 19, 2023 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update August 08, 2023 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants July 11, 2023 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte to Present at the Jefferies Healthcare Conference June 01, 2023 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update May 08, 2023 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte to Present at the BofA Securities 2023 Health Care Conference May 03, 2023 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares April 21, 2023 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte Announces Pricing of $500 Million Public Offering April 19, 2023 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants April 17, 2023 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies April 17, 2023 From Vaxcyte, Inc. Via GlobeNewswire Tickers PCVX Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.